A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)

NCT04809467 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
54
Enrollment
INDUSTRY
Sponsor class

Stopped A business decision was made to discontinue further enrollment. There were no safety concerns that contributed to this decision.

Conditions

Interventions

Sponsor

Incyte Corporation